Dogwood Therapeutics, Inc. (DWTX): Nasdaq/NYSE listing notice — Virios Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period

Dogwood Therapeutics, Inc.

Received Nasdaq notice on Nov 2, 2023; bid price closed below $1.00 for 30 consecutive business days.
Must regain compliance by May 1, 2023 with $1.00+ closing for 10 consecutive days.
If not compliant, may qualify for second 180-day compliance period before delisting threat.
Stock continues trading on Nasdaq Capital Market under symbol VIRI.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 2, 2023, Virios Therapeutics Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capit

View on SEC.gov

Browse all listing & compliance notices →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.